Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-10-09 |
Iris Pharma (France) Keen Eye (France) |
artificial intelligence (AI) applications for bioimaging analysis |
ophtalmological diseases |
collaboration |
Ophtalmological diseases - Technology - Services |
Collaboration agreement |
2018-10-09 |
ERS Genomics (Ireland) GenAhead Bio (Japan) |
CRISPR/Cas9 genome editing technology patents |
|
licensing |
Technology - Services |
Licensing agreement |
2018-10-09 |
Ziopharm Oncology (USA - MA) Precigen (USA - MD) |
Sleeping Beauty |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2018-10-08 |
Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) |
manufacturing platform for gene therapy programs |
|
manufacturing - bioproduction |
Rare diseases - Genetic diseases - Technology - Services |
Production agreement |
2018-10-08 |
eTheRNA immunotherapies (Belgium) |
mRNA manufacturing facility |
|
opening of new premises |
Cancer - Oncology - Technology - Services |
Opening of new premises |
2018-10-08 |
Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company |
lentivirus |
cancers, undisclosed rare disease |
services contract |
Technology - Services |
Services contract |
2018-10-08 |
Cytosen Therapeutics (USA - TX) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-10-05 |
Oxford Biomedica (UK) Orchard Therapeutics (UK) |
lentiviral vectors for ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders |
adenosine deaminase severe combined immunodeficiency (ADA-SCID), mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A), undisclosed follow-on indications. |
collaboration |
Rare diseases - Genetic diseases |
Licensing agreement |
2018-10-05 |
Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) |
AAV1 neurotrophin 3 (NT-3) gene therapy |
Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
2018-10-04 |
Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA) |
- ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
|
hepatitis B |
licensing - research |
Infectious diseases |
Licensing agreement |
2018-10-04 |
Horizon Discovery (UK) Celyad (Belgium) |
shRNA technology |
|
licensing |
Technology - Services |
Licensing agreement |
2018-10-03 |
Boston Pharmaceuticals (USA - MA) Novartis (Switzerland) |
LYS228, IID572, MAK181 |
carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections |
licensing |
Infectious diseases |
Licensing agreement |
2018-10-03 |
Boston Pharmaceuticals (USA - MA) GSK (UK) |
GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs |
acne, irritable bowel syndrome with diarrhea (IBS-D) |
licensing |
Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases |
Licensing agreement |
2018-10-03 |
Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA) |
combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2018-10-03 |
Cellular Biomedicine Group (China) National Cancer Institute (USA) |
next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2018-10-02 |
Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA) |
neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers |
|
research - licensing |
Cancer - Oncology |
Licensing agreement |
2018-10-02 |
Cytosen Therapeutics (USA - TX) KBI Biopharma (USA - NC) |
Natural Killer (NK) cells |
|
bioproduction - manufacturing |
Cancer - Oncology - Technology - Services |
Production agreement |
2018-10-01 |
Editas Medicine (USa - MA) |
senior vice president |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
2018-10-01 |
Melinta Therapeutics (USA - CT) Menarini (Italy) |
Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) |
acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic Gram-negative organisms, infections due to susceptible strains of important designated gram-positive and gram-negative pathogens, including infections due to Acinetobacter species |
licensing - development - commercialisation |
Infectious diseases |
Licensing agreement |
2018-10-01 |
KangStem Biotech (South Korea) MaSTherCell, (Belgium), a subsidiary of Orgenesis (USA - NY) |
Furestem-AD® |
|
manufacturing - bioproduction |
Technology - Services |
Production agreement |